emmaadmin – UCLB

UCLB spinout MeiraGTx Announces Priority Medicines (PRIME) and Advanced Therapy Medicinal Product (ATMP) Designations Granted by the European Medicines Agency to AAV-RPGR Gene Therapy for the Treatment of X-Linked Retinitis Pigmentosa. This technology derives from research undertaken at the UCL Institute of Ophthalmology, London

emmaadmin2020-03-03T10:07:02+00:00

• PRIME designation granted based on clinical data from ongoing Phase 1/2 trial of AAV-RPGR • AAV-RPGR is the only XLRP treatment in development to be awarded P [...]

UCLB spinout MeiraGTx Announces Priority Medicines (PRIME) and Advanced Therapy Medicinal Product (ATMP) Designations Granted by the European Medicines Agency to AAV-RPGR Gene Therapy for the Treatment of X-Linked Retinitis Pigmentosa. This technology derives from research undertaken at the UCL Institute of Ophthalmology, Londonemmaadmin2020-03-03T10:07:02+00:00

Orchard Therapeutics Announces FDA Granted Orphan Drug Designation for OTL-102 for the Treatment of X-linked Chronic Granulomatous Disease (X-CGD)

emmaadmin2020-01-30T11:27:30+00:00

Early Clinical Data Support ex vivo Hematopoietic Stem Cell Gene Therapy as a Potentially Promising Treatment Option for X-CGD BOSTON and LONDON, Jan. 29, 2020 [...]

Orchard Therapeutics Announces FDA Granted Orphan Drug Designation for OTL-102 for the Treatment of X-linked Chronic Granulomatous Disease (X-CGD)emmaadmin2020-01-30T11:27:30+00:00

Somaserve secures IP and global commercial rights to the ‘bionic nanoparticle’ technology PolyNaut®

emmaadmin2019-07-15T10:39:43+01:00

Somaserve Ltd, a newly founded UCLB spinout company from the UCL department of Chemistry, today announced that it has secured the IP and global commercial right [...]

Somaserve secures IP and global commercial rights to the ‘bionic nanoparticle’ technology PolyNaut®emmaadmin2019-07-15T10:39:43+01:00

Orchard Therapeutics Announces $110M Series B Financing to Advance Transformative Gene Therapy Pipeline

emmaadmin2017-12-20T09:53:07+00:00

UCLB spinout company, Orchard Therapeutics, a biotechnology company dedicated to transforming the lives of patients with rare disorders through innovative gene [...]

Orchard Therapeutics Announces $110M Series B Financing to Advance Transformative Gene Therapy Pipelineemmaadmin2017-12-20T09:53:07+00:00

BioMarin Provides 1.5 years of Clinical Data for Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A

emmaadmin2017-12-15T14:45:09+00:00

Valoctocogene Roxaparvovec Demonstrated Sustained Normal or Near Normal Factor VIII Levels in Severe Hemophilia A for Most Patients at Both Doses in Phase 1/2 S [...]

BioMarin Provides 1.5 years of Clinical Data for Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia Aemmaadmin2017-12-15T14:45:09+00:00

UCL spinout company Puridify Limited has been acquired by GE Healthcare

emmaadmin2017-11-30T16:16:10+00:00

UCL spinout company, Puridify Limited, developers of bioprocessing technologies to significantly advance industrial biomolecule manufacture has been acquired by [...]

UCL spinout company Puridify Limited has been acquired by GE Healthcareemmaadmin2017-11-30T16:16:10+00:00

BioMarin’s valoctocogene roxaparvovec a Breakthrough Therapy for hemophilia A

emmaadmin2017-11-10T16:09:24+00:00

BioMarin today announced that the U.S. Food and Drug Administration (FDA) granted valoctocogene roxaparvovec (formally BMN 270) a Breakthrough Therapy Designati [...]

BioMarin’s valoctocogene roxaparvovec a Breakthrough Therapy for hemophilia Aemmaadmin2017-11-10T16:09:24+00:00

Abzena plc and UCL Medical Research Council grant awarded to collaboration group developing novel autoimmune therapy

emmaadmin2017-08-11T16:00:33+01:00

Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), a life sciences group providing services and technologies to enable the development and manufacture of biopharm [...]

Abzena plc and UCL Medical Research Council grant awarded to collaboration group developing novel autoimmune therapyemmaadmin2017-08-11T16:00:33+01:00

Funding of four initial projects and operational update

emmaadmin2017-09-11T10:41:20+01:00

First four drug discovery programmes now launched in collaboration with academics at all three partner universities - spanning a variety of disease areas and dr [...]

Funding of four initial projects and operational updateemmaadmin2017-09-11T10:41:20+01:00

Antibody manufacturing development agreement signed with UCL

emmaadmin2017-08-11T16:27:33+01:00

Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), a life sciences group providing services and technologies to enable the development and manufacture of biopharm [...]

Antibody manufacturing development agreement signed with UCLemmaadmin2017-08-11T16:27:33+01:00

About emmaadmin